L27.0 Generalized skin eruption due to drugs and medicaments taken internally
The ICD-10-CM code for Generalized skin eruption due to drugs and medicaments taken internally is L27.0 (FY2026). It is a billable, claim-ready diagnosis code.
Classification
- Section
- L20-L30: Dermatitis and eczema (L20-L30)
- Category L27
- 6 codes (5 billable)
- FY2026 Status
- Stable since FY2024
Also Known As
ICD-10-CM Alphabetic Index entries that lead to L27.0:
- Rash (toxic) › drug (internal use)
- Eruption › drug (generalized) (taken internally)
- Dermatitis (eczematous) › due to › vaccine or vaccination
- Dermatitis (eczematous) › due to › drugs and medicaments (generalized) (internal use)
- Eruption › skin (nonspecific) › due to inoculation/vaccination (generalized)
U.S. Hospital Utilization
- An estimated 39,910 U.S. inpatient stays in 2023 included L27.0 among the documented diagnoses.
- 3,845 stays listed it as the principal diagnosis.
Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.
Official Coding Guidelines
Pressure ulcer stages—L89 identifies site/stage; code all ulcersa. Pressure ulcer stage codes 1) Pressure ulcer stages Codes in category L89, Pressure ulcer, identify the site and stage of the pressure ulcer. The ICD-10-CM classifies pressure ulcer stages based on severity, which is designated by stages 1-4, deep tissue pressure injury, unspecified stage, and unstageable. Assign as many codes from category L89 as needed to identify all the pressure ulcers the patient has, if applicable. See Section I.B.14. for pressure ulcer stage documentation by clinicians other than patient's provider.
Unstageable pressure ulcers—L89.--0 based on clinical documentation2) Unstageable pressure ulcers Assignment of the code for unstageable pressure ulcer (L89.--0) should be based on the clinical documentation. These codes are used for
Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026